{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.2","upperLimit":"8.3","value":"5.9"},{"groupId":"OG001","lowerLimit":"26.4","upperLimit":"48.0","value":"31.0"},{"groupId":"OG002","lowerLimit":"4.3","upperLimit":"8.3","value":"6.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"51"},{"groupId":"OG002","value":"142"}],"units":"Participants"}],"description":"Progression Free Survival (PFS) is defined as the time in months from the start of treatment to the date of first documented disease progression or death due to any cause, which ever occurs first. PFS on last prior anti-cancer therapy is defined as the time in months from the start of last prior anti-cancer therapy to progression on that therapy.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with a PDGFRA D842V mutation, any line of treatment","id":"OG000","title":"Patients With a PDGFRA D842V Mutation"},{"description":"Patients that do not have a PDGFRA D842V mutation and have received 1 prior line of therapy","id":"OG001","title":"2L Patients Without a PDGFRA D842V Mutation"},{"description":"Patients that do not have a PDGFRA D842V mutation and have had 2 or more prior lines of therapy","id":"OG002","title":"3L Patients Without a PDGFRA D842V Mutation"}],"paramType":"MEDIAN","populationDescription":"Patients enrolled on any dose (Part 1 and Part 2) with data on progression-free survival for the most recent prior therapy","reportingStatus":"POSTED","timeFrame":"Historical data collected at enrollment, all available data on prior therapy was collected","title":"Median PFS on Last Prior Anti-cancer Therapy","type":"SECONDARY","unitOfMeasure":"months"}